Krishna Institu.

Q1 FY27Healthcare Services

Krishna Institu. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹772

Market cap₹32.9K Cr

P/E157.6

Updated25 Aug 2026

Read4 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueRank 3

MarginRank 3

CapexYes

FundraiseYes

Not discussed on this call: order book.

The short version

KIMS Hospitals expects year-on-year growth in top line and bottom line, aiming to maintain historical growth rates seen over the last 10-15 years. KIMS Hospitals expects year-on-year growth in both topline and bottomline, aiming to maintain the historical growth trajectory of the past 10-15 years.

From Krishna Institu.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3

KIMS Hospitals expects year-on-year growth in top line and bottom line, aiming to maintain historical growth rates seen over the last 10-15 years. (Page 23)
Core markets like Telangana, Andhra Pradesh, Maharashtra, Karnataka, and Kerala will be the focus for growth, mainly via greenfield projects and acquisitions. (Pages 19, 23)
New hospitals like Kondapur and Rajahmundry are expected to scale up, with Kondapur showing a 40% revenue growth shortly after commissioning. (Pages 17, 18)
Andhra Pradesh cluster shows strong, continuous growth with addition of specialties like cancer care aiding ARPOB increase. (Page 17)
Utilization in mature clusters is at around 61%-65%, expected to improve to 65%-70% by FY 2030 without adding bed capacity. (Page 15)
They project healthy 20% year-on-year revenue growth in Bangalore and Maharashtra clusters post-stabilization. (Page 12)
Conservative ARPOB growth guidance at 4%-5% going forward. (Page 15)

Profitability & Margins

KIMS Hospitals expects year-on-year growth in both topline and bottomline, aiming to maintain the historical growth trajectory of the past 10-15 years. (Page 23)
EBITDA margins in mature clusters like Telangana are expected to stabilize around 30%-35% once new expansions mature. (Page 19, 22)
Kerala cluster margins are expected around 22%-23%, acknowledging some entry costs but no structural margin impediments. (Page 19)
Operating cash flow is projected to exceed INR 2,500 crore over next 3-4 years, with internal accruals primarily reinvested into growth rather than debt reduction. (Page 19)
Focus on stabilizing existing hospitals before new greenfield expansions in FY '28 and beyond, anticipating profitable growth. (Page 8, 23)
EPS for FY '26 was INR 104; near-term profits may see fluctuations due to new hospital ramp-up and CAPEX cycle, but long-term outlook remains positive. (Pages 3, 22)

See what Krishna Institu. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Current FY '27 CAPEX is around INR 100-125 crore over the next nine months, mostly tied to Rajahmundry hospital (INR 60-75 crore) and minor additional spend in Kondapur and Secunderabad.
Maintenance CAPEX is estimated at around INR 100 crore per year for the next 3-4 years.
Majority of new CAPEX has been completed; future spends will be more focused on consolidating existing assets.
New greenfield hospital opportunities (~300-350 beds, scalable by 100 beds) are primarily planned for FY '28 onwards in core markets (Maharashtra, Kerala, Telangana, Andhra Pradesh); Karnataka will continue via greenfield route.
Brownfield expansions in Kerala, Telangana, Maharashtra are shortlisted and will be pursued when timing is right.
Internal accruals and QIP proceeds are being used for debt reduction and growth-related investments while maintaining prudent debt-equity ratios (~2.5:1).

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

Recently completed a Qualified Institutional Placement (QIP) raising INR 1,500 crores, which was oversubscribed.
INR 1,100 crores of QIP proceeds have already been used to reduce debt.
Preferential allotment to promoters of INR 600 crores approved; 25% to be infused initially, balance later.
Management is maintaining a cautious approach to debt, targeting a debt-equity ratio of around 2.5:1.
No explicit mention of immediate future fundraising through debt or equity; focus is on consolidating and growing within existing financial structure.
Internal accruals expected to be primarily used for expansion and CAPEX rather than further debt reduction in the near term.

See what Krishna Institu. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The document does not explicitly mention any current or expected orderbook or pending orders for KIMS Hospitals. However, relevant insights related to growth opportunities and expansions include: - Focus on core markets for acquisitions: Maharashtra, Kerala, Telangana, Andhra Pradesh. - Karnataka growth primarily via greenfield projects. - Typical acquisition targets: hospitals with 300-350 beds, scalable by ~100 beds. - Pursuit of acquisitions and greenfield projects is ongoing but uncertain; no definite numbers on closures. - Several O&M (Operations & Maintenance) agreements with hospitals in Telangana and Andhra pending integration and potential acquisition. - Emphasis on stabilizing recently commissioned hospitals before further expansions. - Plans to balance debt and growth cautiously; expected continued year-on-year top line and bottom line growth. No specific orderbook or pending orders are cited.

Krishna Institu. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹33 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krishna Institu.'s management said in earlier quarters

Others in Healthcare Services this season

Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krishna Institu. Q1 FY27 results?

What is Krishna Institu. share price analysis?

Krishna Institu. currently shows a below-average growth signal. The stock trades at a P/E of 157.6 with a market cap of ₹32,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krishna Institu. planning capital expenditure?

Current FY '27 CAPEX is around INR 100-125 crore over the next nine months, mostly tied to Rajahmundry hospital (INR 60-75 crore) and minor additional spend in Kondapur and Secunderabad.

Keep Krishna Institu. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.